Siga Technologies approved in Japan for treatment of orthopoxviruses
Regulatory Approval: Siga Technologies' antiviral treatment Tepoxx has received regulatory approval in Japan for treating smallpox, mpox, cowpox, and complications from smallpox vaccination in both adults and pediatric patients over 13 kg.
Strategic Stockpile: Tepoxx is now part of Japan's strategic national stockpile, with Siga partnering with Japan Biotechno Pharma for distribution; it is already approved in the U.S., Canada, E.U., and U.K. for similar uses.
Get Free Real-Time Notifications for Any Stock
Analyst Views on SIGA
About SIGA
About the author
Daily Upgrade Report for Validea Motley Fool Strategy - September 4, 2025
Stock Upgrade: SIGA Technologies Inc. received an upgrade in its rating from 53% to 80% based on the Motley Fool's small-cap growth investor strategy, indicating increased interest in the stock due to its strong fundamentals and valuation.
Company Overview: SIGA Technologies is a pharmaceutical company focused on developing antiviral medicines, with its flagship product TPOXX approved for treating smallpox and other orthopoxvirus-related diseases in various regions.
Healthcare Sector Struggles, Yet These Yields Reaching 7% Might Still Be Viable
Healthcare Stocks Overview
- Market Performance: Healthcare stocks have remained stagnant since April, contrasting sharply with the S&P 500, which has surged by 27%. This stagnation has drawn the attention of contrarian investors looking for potential bargains or yield traps in the sector.
Key Healthcare Stocks
Omega Healthcare Investors (OHI): Offers a 6.4% yield and operates skilled nursing and assisted living facilities with a portfolio of 93,961 beds across over 1,000 properties. The company has shown recovery post-COVID, beating estimates for adjusted funds from operations (AFFO) and raising its full-year guidance. However, shares are trading at over 13 times next year's AFFO estimates, indicating a moderate valuation.
LTC Properties (LTC): With a 6.3% yield, LTC is transitioning some contracts to RIDEA-structured agreements, which could enhance growth potential. Currently, 7% of its enterprise value comes from this segment, with plans to double it by year-end.
Healthpeak Properties (DOC): This REIT has a 7.0% yield and a diverse portfolio including outpatient medical facilities and laboratories. The dividend was recently raised and converted to a monthly payout, but growth may be limited due to challenges in its life sciences segment.
Sila Realty Trust (SILA): A newer entrant with a 6.4% yield, SILA has delivered nearly 20% total returns since its IPO in June 2024. It has a solid financial position with long lease terms and a well-covered payout, although it reverted from a monthly to a quarterly dividend.
Pharmaceutical Sector Insights
Siga Technologies (SIGA): Offers a high yield of 7.1%, but is considered too concentrated as a single-drug company. Its future growth depends on diversification.
Bristol-Myers Squibb (BMY): A blue-chip pharmaceutical company with a market cap of nearly $100 billion and a 5.3% yield. Despite its diversified product line, BMY has underperformed, with a 25% decline in share price over five years. However, it recently beat earnings estimates and is forming strategic partnerships.
Pfizer (PFE): Currently yielding 6.9%, Pfizer has faced challenges, including the cancellation of a weight-loss drug trial and declining COVID-related sales. The company is targeting $7 billion in cost savings by 2027, but its dividend remains secure for now with a 55% payout ratio.
Investment Strategy
- Retirement Income Strategy: The article emphasizes the importance of generating income through dividends to avoid depleting capital in retirement. A proposed "No Withdrawal" portfolio could yield $40,000 annually from a $500,000 investment, highlighting the potential for high-yield investments to support retirement without touching the principal.
This analysis suggests that while healthcare stocks have been overlooked, there are opportunities for income-focused investors, particularly in REITs and select pharmaceutical companies.
